Morton Grove

“You should immediately and comprehensively assess your company‘s global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to (US) FDA requirements,” US FDA said.

CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief

In a blow to Wockhardt, the US FDA has issued a warning letter to company's US subsidiary CP Pharma.

Wockhardt up 5% as USFDA excludes Ceftriaxone from import alert

Wockhardt shares rallied nearly 5 percent intraday Tuesday after the US health regulator excluded an antibiotic drug Ceftriaxone sodium from the import alert.

Wockhardt rises 5% on Citi upgrade post firm Q3 results

Citi has even increased its FY16-17 core EPS by 2/10 percent based on progress on regulatory front and stated that resolution of 483s at Morton Grove is positive. It also adds that risk-reward looks reasonable for Wockhardt.